DoubleGood AB Report issue

For profit
Founded: Lund Sweden (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2015
NCT02487680
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

DoubleGood AB

Active Ingredients

Drugs in Other Trials (2)

amino acids (Freamine) (2 trials)

chromium (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 2
  • # of Trial APIs: 2